New Antibiotics Show Promise Against Rising, Drug-Resistant Tuberculosis
A team of international researchers has identified how three experimental antibiotic compounds disrupt Mycobacterium tuberculosis, the bacterium that causes tuberculosis (TB), potentially paving the way for new treatments against the world’s leading infectious killer. The findings, published in Nature Communications, detail how ecumicin, ilamycins, and cyclomarins target a crucial bacterial machine responsible for clearing out damaged proteins.
TB, a preventable and curable disease, claimed 1.23 million lives in 2024, including 150,000 among people living with HIV, according to the World Health Organization (WHO). Globally, an estimated 10.7 million people fell ill with TB in the same year. While existing treatments are available, the rise of drug-resistant strains and the lengthy duration of therapy – often months – pose significant challenges.
The research focused on the ClpC1–ClpP1P2 complex, a molecular machine essential for protein recycling within the bacterium. “TB bacteria depend on this recycling system to stay alive, particularly under stressful conditions inside the human body,” explained immunologist Warwick Britton of the University of Sydney in Australia. “Our findings show these compounds don’t simply shut the system down. Instead, each one interferes with it in a different way, triggering widespread imbalances across the whole bacterium. This disruption weakens its ability to function and survive.”
Researchers analyzed over 3,000 proteins within M. Tuberculosis to observe the effects of each antibiotic compound. Ecumicin demonstrated the most significant impact, causing a spike in the protective stress protein Hsp20, indicating severe bacterial stress. The varying mechanisms of disruption suggest potential for combining these compounds to maximize effectiveness.
The WHO has identified multidrug-resistant TB (MDR-TB) as a major public health crisis and health security threat, noting that only about 2 in 5 people with drug-resistant TB accessed treatment in 2024. The emergence of resistance is often linked to incomplete treatment courses and the bacterium’s ability to adapt.
“By tracking changes across most of the bacterium’s protein network, we were able to see how disrupting a single essential complex can reshape the bacterium’s entire internal protein landscape,” said chemical biologist Isabel Barter of the University of Sydney. “This deeper understanding gives us valuable insight into how we might refine these compounds and design more precise and effective anti-TB treatments.”
Chemical biologist Richard Payne, also of the University of Sydney, added, “Our study highlights the potential of directly targeting this protein degradation system. By understanding how different compounds interact with it and disrupt its normal function, One can more strategically design the next-generation of anti-TB drugs.”
The WHO estimates that approximately a quarter of the global population has been infected with TB bacteria, though most do not develop active disease. Individuals with weakened immune systems, such as those with HIV, diabetes, or malnutrition, are at higher risk of progressing to active TB. TB is present in all countries and age groups, with Bangladesh, China, India, Indonesia, Nigeria, Pakistan, Philippines and South Africa accounting for roughly half of all cases globally.